Glenzocimab
Glenzocimab Basic information
- Product Name:
- Glenzocimab
- Synonyms:
-
- Glenzocimab
- Research Grade Glenzocimab (DHJ60601)
- ACT017
- Research Grade Glenzocimab
- Glenzocimab (anti-GP6)
- CAS:
- 2101829-58-5
- MW:
- 0
- Mol File:
- Mol File
More
Less
Glenzocimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Glenzocimab Usage And Synthesis
Uses
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke[1][2].
in vivo
ACT017 (1-8 mg/kg; i.v.) inhibits collagen-induced platelet aggregation in cynomolgus monkeys[2].
| Animal Model: | Cynomolgus monkeys[2] |
| Dosage: | 1-8 mg/kg |
| Administration: | I.v. |
| Result: | Reversibly inhibited collagen-induced platelet aggregation, at 2 to 8 mg/kg doses, collagen-induced platelet aggregation measured 0.5 hour after the end of the administration was fully inhibited for all cynomolgus. |
References
[1] Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022 Nov;53(11):3506-3513. DOI:10.1161/STROKEAHA.122.039790
[2] Lebozec K, et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks. MAbs. 2017 Aug/Sep;9(6):945-958. DOI:10.1080/19420862.2017.1336592
GlenzocimabSupplier
Shanghai YuanYe Biotechnology Co., Ltd.
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
ShangHai Biochempartner Co.,Ltd
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
TargetMol Chemicals Inc.
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
Wuhan Chemstan Biotechnology Co., Ltd.
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
TargetMol Chemicals Inc.
- Tel
- 4008200310
- marketing@tsbiochem.com